You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 4127 results
  1. AMES+Brain Stimulation: Treatment for Profound Plegia in Stroke

    SBC: AMES TECHNOLOGY, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): An estimated 30% of chronic stroke patients with motor disabilities of the limbs are plegic in the hand or the foot - that is, they cannot move the hand or foot. While some plegic stroke patients have completely paralyzed muscles, without the ability to activate even minimally the plegic muscles ( profound plegia ), other plegic stroke patients are capable of p ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Platelet-based Nanoparticle Therapy for Prostate Cancer

    SBC: ANDROBIOSYS, INC.            Topic: NCI

    The goal of this Phase II proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix particles) that contains super paramagnetic iron oxide (SPIO) nanoparticles. The Phase I program showed that SPIO-Stasix particles selecti ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. A Pilot Clinical Study in Acute STEMI

    SBC: Angion Biomedica Corp.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Percutaneous coronary intervention (PCI) has become the mainstay for treatment of ST-segment elevation myocardial infarction (STEMI). Whereas early recanalization undoubtedly salvages myocardial tissue, reperfusion following prolonged ischemia can also exacerbate injury. Infarct size needs to be limited, and the conditions favoring adaptive ventricular healing ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Anti-Fibrotic Therapy for Scleroderma/SSc

    SBC: Angion Biomedica Corp.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is an autoimmune disorder characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, esophagus, intestine, and kidney. Many patients who suffer from scleroderma/SSc also have a loss of pulmonary function. Scleroderma/SSc affects approximately 400,0 ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic Potential of PARP inhibitor for Acute Pancreatitis

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Acute Pancreatitis (AP) is a potentially lethal inflammatory disease of the pancreas. Its pathogenesis remains obscure and is involved in a process of acute inflammation and necrosis in the pancreas, with variable involvement of regional tissues or organ systems that leads to a systemic inflammatory response. AP contributes to thousands of annual hospital admis ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Phase I Clinical Study Using an Antifibrotic Drug

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of people worldwide, is the liver scarring response to chronic injury from excessive alcohol use, virus infection (hepatitis B and C), iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are exp ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Treatment for alcoholic liver disease

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leading cause of death in the United States and afflicts hundreds of millions of people worldwide. Alcohol intake remains the most important cause of l ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Therapeutic for Chronic Kidney Disease

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION: Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Current therapeutic strategies for the treatment of CKD include changes in life-style and/or medications to alleviate the underlying cause of disease. Since renal disease is ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Antifibrotic Therapy for Chronic Kidney Disease

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Chronic kidney disease remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic strategies oppose the molecular and cellular program of fibrosis that drives renal disease. For decades, ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. PDGFR and KDR Inhibitors for Liver Fibrosis

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are expected to tr ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government